Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | POLG | P54098 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1224879 | 0.84 | EP300 (0.46) | ALBEP300 | |
| SCHEMBL12883799 | 0.80 | EP300 (0.39) | ALBEP300POLG | |
| SCHEMBL7122663 | 0.80 | ALDH1A1 (0.35) | ALBEP300POLG | |
| SCHEMBL12883801 | 0.80 | ALB (0.34) | ALBEP300POLG | |
| SCHEMBL12883796 | 0.78 | EP300 (0.36) | ALBEP300 | |
| SCHEMBL12883793 | 0.78 | EP300 (0.38) | ALBEP300 | |
| SCHEMBL2470522 | 0.77 | LMNA (0.39) | EP300NPC1 | |
| SCHEMBL1223628 | 0.77 | KDM4E (0.41) | NPC1 | |
| SCHEMBL7064563 | 0.76 | EP300 (0.41) | EP300NPC1 | |
| SCHEMBL12883788 | 0.76 | POLB (0.40) | PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166606-A1 | 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients | KOLON INDUSTRIES, INC. (KR) | 2003-09-04 | — | — | US | disclosed |
| EP-1311524-A2 | 5'-DEOXY-N-(SUBSTITUTED OXYCARBONYL)-5-FLUOROCYTOSINE AND DERIVATIVES THEREOF, METHOD OF PREPARING SAME, AND ANTICANCER COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENTS | Kolon Industries, Inc. (KR) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002011668-A2 | 5'-DEOXY-N-(SUBSTITUTED OXYCARBONYL)-5-FLUOROCYTOSINE AND DERIVATIVES THEREOF, METHOD OF PREPARING SAME, AND ANTICANCER COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENTS | KOLON INDUSTRIES, INC. (KR) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166606-A1 | 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients | DUT, RNGTT, MTAP | ALB 1195/4885EP300 3927/4885NPC1 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.